

# Clinical Trial Protocol Optimization and Design Congress

Promote Collaboration and Understanding  
Between All Stakeholders in Protocol Development  
to Optimize Outcomes and Improve Patient Care

## FEATURED SPEAKERS



**Jim Kremidas**  
Executive Director,  
**ASSOCIATION OF  
CLINICAL RESEARCH  
PROFESSIONALS**



**Sheri Kuss**  
Associate Director,  
Trial Optimization and  
Standards, **TEVA**



**Richard Murray**  
Vice President and  
Deputy Chief Patient  
Officer, **MERCK**



**Mary Westrick**  
Adjunct Faculty (Phase I  
Clinical Trials Specialty),  
**UNIVERSITY OF  
WISCONSIN, MADISON**



**Kunal Sampat, MNA**  
Senior Manager, Clinical  
Programs, **ABBOTT  
VASCULAR**



**Rosemarie Pincus, Ph.D.**  
Principal Medical Writing  
Scientist, Oncology  
Division, **JOHNSON &  
JOHNSON**

## TOP 2017 SESSIONS

- Design Protocols to Embrace Reality: A Phase I Perspective
- **CASE STUDY:** Consider the Site Perspective on Protocols to Build Strategic Relationships that Promote Clinical Success
- Write Quality Protocols to Focus on Streamlining, Clarity and Consistency Within the Study Documents
- **ROUNDTABLE DISCUSSION:** Examine the Potential Outcomes of Building a Consistent Protocol Template
- Integrate Wearable Technology with Protocols to Improve Clinical Data Gathering and Patient Centricity
- Review How Protocol Design Is Flawed and Affecting Clinical Research
- **PROVIDER PANEL:** Gain the Site and Patient Perspective
- Explore the Four P's Surrounding Patient Centricity

## KEY OBJECTIVES

- **Improve** clinical research operations with optimized protocols that incorporate stakeholder perspectives
- **Discuss** new techniques to optimize trial protocols and recognize time and physiological constraints
- **Understand** the importance of intelligent protocol design and how it translates to improved clinical trial success and patient care
- **Share** techniques and best practices with other pharmaceutical industry professionals to implement a consistent and qualified industry standard
- **Incorporate** site input early in the protocol writing stage to increase collaboration across the study and expedite the protocol process

SPONSOR



## Dear Colleague,

Clinical protocols are the framework for a clinical trial. From the amount of samples to take from a patient to the time frame and schedule for the study, protocols ensure every detail, incident or outcome is planned for and recorded. Over the past few years, protocols have been under tremendous scrutiny for their feasibility and lack of insight and flexibility regarding patient limits and site resources. This absence of collaboration causes major delays in study start-up timelines. A contributing factor to these missteps is the use of non-practicing physicians from pharmaceutical companies, many of whom have never seen a patient outside their residency, to write and form these complex documents with limited knowledge of how long a procedure takes or its effect on a patient's health. The document then goes through scientific review, which should catch the missteps mentioned before, but instead causes procedure inflation, adding unneeded and costly steps to the process. The issues with the current status quo go on, but the **2017 Trial Protocol Optimization and Design Congress** will foster a space for professionals to improve the industry and its processes.

Protocol optimization has made a resurgence as a major component of the pharmaceutical industry. Sponsors, sites and CROs are noticing how inflated protocols have become, how protocol amendments are costing companies millions, and how protocols are unrealistic for patients to participate in and practitioners to operate. The summit explores how protocol optimization will improve inclusion/exclusion criteria, reduce the time each procedure takes and help life science professionals better understand what is physiologically possible to accomplish with a patient. Protocol optimization will improve patient care and outcomes, site performance and recruitment, and the bottom line for drug development.

The 2017 Clinical Trial Protocol Optimization Congress will bring decision-makers from sites, pharma, CROs and other stakeholders in the protocol writing process together to discuss how the industry should change their policies and procedures. With topics on inclusion/exclusion, advisory boards, training for protocol writers and patient feasibility, the congress will foster a space the industry can build upon in order to improve all aspects of clinical trial protocol optimization and design.

I look forward to welcoming you to Philadelphia in July!

Sincerely,

**Tyler Lobo**

Tyler Lobo

Conference Production Director

ExL Events, a Division of Questex, LLC

## WHO SHOULD ATTEND

This conference is designed for professionals from clinical research sites and pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:

- Protocol Optimization/Design/ Planning
- Trial Optimization/Design
- Protocol Management
- Protocol Writing
- Clinical Operations
- Clinical Research
- Regulatory Affairs
- R&D Operations
- Quality Assurance
- Patient Centricity
- Process Optimization
- Site Relations
- Trial/Clinical Compliance
- Process Improvement
- Clinical Safety
- Site/Trial Feasibility

This event may also be of interest to:

- Clinical/Academic Research Organizations
- Protocol Writing Software Providers
- Clinical Trial Management Software Companies
- Clinical Trial Optimization Services
- Protocol Consultants



## VENUE

**Sheraton Philadelphia  
University City Hotel**

3549 Chestnut St., Philadelphia, PA 19104

To make reservations please call 1-888-627-7070 and request the negotiated rate for ExL's Real-World Evidence and 2017 Trial Protocol Optimization Design Congress Meetings. You may also make reservations online at <http://bit.ly/2ooGqhE>. The group rate is available until June 30, 2017. Please book your room early as rooms available at this rate are limited.

*\*ExL Events is not affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, housing bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. In the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly email us at [info@exlevents.com](mailto:info@exlevents.com). ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL's reserved guest room block using the details provided.*

## SPONSORSHIP AND EXHIBITION OPPORTUNITIES

Do you want to spread the word about your organization's solutions and services to potential clients who will be attending this event?

Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event or distribute promotional items to attendees. ExL Events will work closely with you to customize a package that will suit all of your needs.

# Agenda // Day One – Monday, July 17, 2017

8:00 Continental Breakfast and Registration

9:00 Chairperson's Opening Remarks

## PROTOCOL PAIN POINTS

### 9:15 Review How Protocol Design Is Flawed and Affecting Clinical Research

- Hear examples of current flaws and issues with clinical trial protocols and how they affect the industry and the patient
- Understand why we need to construct processes that promote quality, speed and equity in trial start-up activities and protocol implementation
- Discuss how optimizing protocol design processes could provide intelligent solutions to issues surrounding research operations and patient care

**Richard Murray**, *Vice President and Deputy Chief Patient Officer*, **MERCK**

### 10:00 Apply Quality by Design Techniques During Protocol Development to Decrease Complexity and Risk

- Review the ramifications of overly complex clinical trial protocols, including their impact on compliance, risks, costs, amendments and enrollment
- Highlight Quality by Design (QbD) principles and tools to decrease risk and unnecessary procedures within a protocol
- Identify risk management and protocol optimization techniques to reduce costly amendments and inefficient trials

**Sheri Kuss**, *Associate Director, Trial Optimization and Standards*, **TEVA**

10:45 Networking Break

### 11:15 Discuss the Disconnect Between Protocol Design and the Capabilities of All Stakeholders

- Generate a two-way conversation between stakeholders in the clinical trial industry to better respond to feedback on time tables, operational feasibility and physiological constraints
- Understand how protocols should be written and designed to be applicable to the practitioners and patients conducting the research
- Accept and apply feedback from other stakeholders to the design process and integrate that feedback in a cohesive and positive manner

**Jim Kremidas**, *Executive Director*, **ASSOCIATION OF CLINICAL RESEARCH PROFESSIONALS**

12:00 Luncheon

## PARTNERSHIPS IN PATIENT CENTRICITY

### 1:00 Engage the Patient Perspective in Clinical Trial Protocol Design to Ensure Patient Centricity and Healthy Outcomes

- Recognize where the trial ends and the patient begins – work to view patients as people, not subjects
- Collaborate to ensure protocols are feasible and equitable for those being tested and those doing the testing
- Incorporate the patient in every point of design to promote recruitment, outcomes and adherence

**William Smith, M.D., FACC**, *President*, **NEW ORLEANS CENTER FOR CLINICAL RESEARCH**

### 1:45 Improve Inclusion and Exclusion Criteria to Safeguard Successful Patient Recruitment and Retention

- Evaluate the impact of “nice-to-have” inclusion and exclusion criteria on clinical trial enrollment
- Ask the right questions to the right people to prevent repeated and expensive protocol amendments
- Collaborate cross-functionally with all stakeholders to determine if delayed enrollment is worth the risk

**Kunal Sampat, MNA**, *Senior Manager, Clinical Programs*, **ABBOTT VASCULAR**

2:30 Networking Break

### 3:00 PROVIDER PANEL: Gain the Site and Patient Perspective



- Assess implementing an initiative to understand patient and site partnerships at a clinical level and how they apply those insights to clinical trials
- Consider the effect a program involving these perspectives might have on clinical trial quality and patient health outcomes
- Gauge the relationship health between pharmaceutical companies and their sites and how an initiative would improve and build a bond between them

**Jeff Kingsley**, *Chief Executive Officer*, **IACT HEALTH**

**William Smith, M.D., FACC**, *President*, **NEW ORLEANS CENTER FOR CLINICAL RESEARCH**

**Mary Westrick**, *Adjunct Faculty (Phase I Clinical Trials Specialty)*, **UNIVERSITY OF WISCONSIN, MADISON**

**Ashish Atreja**, *Chief Technology Engagement and Innovation Officer*, **ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI**

### 4:00 Leverage Patient Insight for Protocol Optimization and Develop Patient-Focused Communications

- Work alongside the patient to understand roadblocks in literature and develop more reader-friendly documents
- Ensure the patient is the center of the trial starting with the literature provided to them at recruitment until the end of the trial, keeping them informed with dignity and respect
- Capitalize on patient insight to improve recruitment activities that envelope a more diverse and educated population

**Madeline Geday**, *Associate Director, Clinical Research, Global Trial Optimization*, **MERCK**

### 4:45 Explore the Four P's Surrounding Patient Centricity

- Discuss why and how issues in patient enrollment continue to plague the industry
- Identify and address the problems in enrollment by using innovative and customized techniques
- Clarify how metrics and figures to predict protocol success shouldn't be solely relied on for recruitment
- Focus on the psychological factor behind each individual person during recruitment to improve practices and results

**Kate Vila**, *Founder & Business Development Manager*, **OPULENT GROUP, LLC**

5:30 Day One Concludes

# Agenda // Day Two – Tuesday, July 18, 2017

8:00 Continental Breakfast

8:45 Chairperson's Recap of Day One

## TRIAL PROTOCOL DESIGN AND OPTIMIZATION

9:00 **Design Protocols to Embrace Reality: A Phase I Perspective**

- Focus efforts to use realistic and pragmatic criteria when recruiting and qualifying subjects
- Conduct a "reality check" on your protocol design to identify pitfalls or obstacles
- Consider a less-than-perfect population to better understand the possible effects of a drug on a real-world subject

**Mary Westrick, Adjunct Faculty (Phase I Clinical Trials Specialty), UNIVERSITY OF WISCONSIN, MADISON**

9:45 **Realize the Benefits of Reliable Adherence Data Through the Introduction of Electronic Compliance Monitors Early in Trial Design**

- Discuss the widely accepted premise that patients aren't always compliant with medication instructions and dosing
- Discover how medication non-adherence injects error into clinical trials, leading to inaccurate results affecting protocol optimization
- Hear how having valuable electronic adherence data can be quantified and used as a source of statistical power in your trial design
- Look at the relationship between electronic adherence monitors and your ROI

**Allan Wilson, M.D., Ph.D., President, INFORMATION MEDIARY CORPORATION**

10:30 Networking Break

11:00 **CASE STUDY: Consider the Site Perspective on Protocols to Build Strategic Relationships that Promote Clinical Success**



- Incorporate the site perspective to improve protocol writing and procedures that create realistic processes and trial frameworks
- Use feedback from sites not just as a requirement, but as a resource to optimize the trial by eliminating expensive, needless and even invasive procedures
- Resolve areas of contempt with site partners that often cause tension, which can create roadblocks and pitfalls for study start-up

**Jeff Kingsley, Chief Executive Officer, IACT HEALTH**

11:45 **Gauge the Impact of Trial Data Collection and Analysis on the Sponsor and Patients**

- Consider the significant impact on the patient and sponsor if data is not collected and/or analyzed properly
- Share the current and future state-of-the-art methods for data collection and analysis via case examples
- Hear recommendations for a clinical trial professional's day-to-day work during data collection and analysis

**Patrick Hu, Senior Safety Physician, ASTRAZENECA**

12:30 Lunch

## INDUSTRYWIDE SOLUTIONS AND CONSISTENCY

1:30 **Write Quality Protocols to Focus on Streamlining, Clarity and Consistency Within the Study Documents**

- Discuss techniques for organizing time and event schedules for ease of layout and understanding
- Keep a clear "line of sight" to minimize the number of study assessments and to align objectives to endpoints of study procedures
- Add flexibility to a study protocol by use of adaptive design to prevent controllable amendments
- Learn checks and balances that promote the quality of a protocol or amendment

**Rosemarie Pincus, Ph.D., Principal Medical Writing Scientist, Oncology Division, JOHNSON & JOHNSON**

2:15 Networking Break

2:45 **Integrate Wearable Technology with Protocols to Improve Clinical Data Gathering and Patient Centricity**

- Introduce the many new devices, techniques and software programs that have come to market for clinical research
- Understand the amount of data wearables can deliver and how to analyze it efficiently
- Overcome obstacles to the adoption of wearable technology presented by patients, sites and other members of the industry

**Ashish Atreja, Chief Technology Engagement and Innovation Officer, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI**

3:30 **ROUNDTABLE DISCUSSION: Examine the Potential Outcomes of Building a Consistent Protocol Template**



- Shape the way the industry will build a consistent protocol template that encompasses all essential elements of the protocol while maintaining clinical integrity
- Adhere to the fundamental tenets of change management to navigate the evolution of protocol development
- Conceptualize the positive or negative outcomes that a consistent protocol template can provide and determine the depth of changes that should be made

**If you are interested in participating in this session, please contact Tyler Lobo at [tlobo@exlevents.com](mailto:tlobo@exlevents.com).**

4:15 Chairperson's Closing Remarks

4:30 Conference Concludes

*"I've had the privilege of participating in and presenting at several ExL Pharma conferences in the US and Europe. This company arranges some of the best-organized and informative industry conferences in my experience."*

–Senior Director, Oncology Field Operations, **SANOFI-AVENTIS**

**REGISTRATION**  
to register [CLICK HERE](#) or

**Call: 201 871 0474**  
**fax: 253 663 7224**  
**email: [register@pmaconference.com](mailto:register@pmaconference.com)**  
**web: <http://pmaconference.com/>**  
**Mail: POB 2303 Falls Church Va 22042**

**Registration Fees for Attending ExL's 2017 Trial Protocol Optimization and Design Congress**

<b>EARLY BIRD PRICING – Register Before June 2, 2017</b>	
Conference .....	\$1,795
<b>STANDARD PRICING – Register After June 2, 2017</b>	
Conference .....	\$1,995
<b>ONSITE PRICING</b>	
Conference .....	\$2,195

**TERMS AND CONDITIONS:** By registering for an ExL Events ("ExL") event, you agree to the following set of terms and conditions listed below:

**REGISTRATION FEE:** The fee includes the conference, all program materials, and designated continental breakfasts, lunches and refreshments.

**PAYMENT:** Make checks payable to ExL Events and write C923 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

**\*\*Please Note:** There will be an administrative charge of \$300 to substitute, exchange and/or replace attendance badges with a colleague within five business days of any ExL conference.\*\*

**CANCELLATION AND REFUND POLICY:** If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event:

- Four weeks or more: A full refund (minus a \$295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date.
- Less than four weeks: A voucher to another ExL event valid for 12 months from the voucher issue date.
- Five days or less: A voucher (minus a \$395 processing and documentation fee) to another ExL event valid for 12 months from the voucher issue date.

To receive a refund or voucher, please email [cancel@exlevents.com](mailto:cancel@exlevents.com)

**CREDIT VOUCHERS:** Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applicable now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees' behalf, the credit voucher will no longer be valid.

ExL Events does not and is not obligated to provide a credit voucher to registered attendee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event.

**Group Discount Program**

Offers may not be combined. Early bird rates do not apply. To find out more about how you can take advantage of these group discounts, please call 201 871 0474.

- 25%** **Save 25% per person when registering four**  
For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time). This is a savings of 25% per person.
- 15%** **Save 15% per person when registering three**  
Can only send three? You can still save 15% off of every registration.

**SUBSTITUTION CHARGES:** There will be an administrative charge of \$300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare, hotel or any other expenses incurred by registrants.

ExL Events' liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date, content, speakers and/or venue.

\*The opinions of ExL's conference speakers do not necessarily reflect those of the companies they represent, nor ExL Events.

Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL's designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL's designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. EXL EVENTS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third-party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.



**Questions? Comments?**

Do you have a question or comment that you would like to be addressed at this event? Would you like to get involved as a speaker or discussion leader?

**MEDIA PARTNERS**



# Clinical Trial Protocol Optimization and Design Congress

Promote Collaboration and Understanding  
Between All Stakeholders in Protocol Development  
to Optimize Outcomes and Improve Patient Care

## FEATURED SPEAKERS



**Jim Kremidas**  
Executive Director,  
**ASSOCIATION OF  
CLINICAL RESEARCH  
PROFESSIONALS**



**Sheri Kuss**  
Associate Director,  
Trial Optimization and  
Standards, **TEVA**



**Richard Murray**  
Vice President and  
Deputy Chief Patient  
Officer, **MERCK**



**Mary Westrick**  
Adjunct Faculty (Phase I  
Clinical Trials Specialty),  
**UNIVERSITY OF  
WISCONSIN, MADISON**



**Kunal Sampat, MNA**  
Senior Manager, Clinical  
Programs, **ABBOTT  
VASCULAR**



**Rosemarie Pincus, Ph.D.**  
Principal Medical Writing  
Scientist, Oncology  
Division, **JOHNSON &  
JOHNSON**

**REGISTRATION**  
to register *CLICK HERE* or

**Call: 201 871 0474**  
**fax: 253 663 7224**  
**email: [register@pmaconference.com/](mailto:register@pmaconference.com)**  
**web: <http://pmaconference.com/>**  
**Mail: POB 2303 Falls Church Va 22042**

YES! Register me for this conference!

Name: \_\_\_\_\_ Title: \_\_\_\_\_

Company: \_\_\_\_\_

Dept.: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Email: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Method of Payment:  Check  Credit Card

Make checks payable to ExL Events.

Card Type:  MasterCard  Visa  Discover  AMEX

Card Number: \_\_\_\_\_

Exp. Date: \_\_\_\_\_ CVV: \_\_\_\_\_

Name on Card: \_\_\_\_\_

Signature: \_\_\_\_\_

Please contact me:

I'm interested in marketing opportunities at this event.

I wish to receive email updates on ExL Pharma's upcoming events.

CONFERENCE CODE: C923